Tesamorelin
The EGRIFTA WR label describes a specific indication, not general weight-loss use.
An approved indication is specific.
The FDA-approved EGRIFTA WR label identifies tesamorelin as a growth hormone-releasing factor analog indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.
The label says it is not indicated for weight-loss management. It also states that long-term cardiovascular safety has not been established.
Approval of this specific prescription product and indication should not be extended to every compounded product or broader wellness claim. Discuss treatment questions with a licensed clinician; this page is not prescribing advice.
Original source: Tesamorelin ↗
Interpretation is limited to the source linked above. Independent medical review pending.